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Abstract
Background: Brain-derived neurotrophic factor (BDNF) has been shown to be a moderator of neuroplasticity. A frequent 
BDNF-polymorphism (Val66Met) is associated with impairments of cortical plasticity. In patients with schizophrenia, 
reduced neuroplastic responses following non-invasive brain stimulation have been reported consistently. Various 
studies have indicated a relationship between the BDNF-Val66Met-polymorphism and motor-cortical plasticity in healthy 
individuals, but schizophrenia patients have yet to be investigated. The aim of this proof-of-concept study was, therefore, 
to test the impact of the BDNF-Val66Met-polymorphism on inhibitory and facilitatory cortical plasticity in schizophrenia 
patients.
Methods: Cortical plasticity was investigated in 22 schizophrenia patients and 35 healthy controls using anodal and cathodal 
transcranial direct-current stimulation (tDCS) applied to the left primary motor cortex. Animal and human research indicates 
that excitability shifts following anodal and cathodal tDCS are related to molecular long-term potentiation and long-term 
depression. To test motor-cortical excitability before and after tDCS, well-established single- and paired-pulse transcranial 
magnetic stimulation protocols were applied.
Results: Our analysis revealed increased glutamate-mediated intracortical facilitation in met-heterozygotes compared 
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butyric-acid-mediated short-interval intracortical inhibition, whereas healthy met-heterozygotes displayed the opposite 
effect. The BDNF-Val66Met-polymorphism did not influence single-pulse motor-evoked potential amplitudes after tDCS.
Conclusions: These preliminary findings support the notion of an association of the BDNF-Val66Met-polymorphism with 
observable alterations in plasticity following cathodal tDCS in schizophrenia patients. This indicates a complex interaction 
between inhibitory intracortical interneuron-networks, cortical plasticity, and the BDNF-Val66Met-polymorphism. Further 
replication and validation need to be dedicated to this question to confirm this relationship.
Keywords: brain-derived neurotrophic factor, motor-cortical plasticity, schizophrenia, transcranial direct current stimulation, 
transcranial magnetic stimulation
Introduction
Brain-derived neurotrophic factor (BDNF) has been shown to be a 
moderator of neuroplasticity in the central nervous system through 
its activity-dependent release, and by balancing the intrasynaptic 
ratio with its precursor peptide pro-BDNF (Aicardi et al., 2004; Woo 
et al., 2005; Miyamoto, 2006). In healthy subjects, the BDNF G196A 
polymorphism, which results in a valine-to-methionine substitu-
tion at the amino-acid position 66 (Val66Met), has been consist-
ently shown to reduce activity-dependent BDNF-secretion, to be 
involved in the regulation of activity- and stimulus-dependent 
plasticity and memory processes, and to influence episodic mem-
ory and learning processes (Egan et al., 2003; Pezawas et al., 2004; 
Woo et al., 2005; Miyamoto, 2006; Caroni et al., 2012). The impact of 
this BDNF-Val66Met-polymorphism on global and local (e.g., hip-
pocampus) brain volumes is still subject to discussion (Molendijk 
et al., 2012). Further studies have addressed the influence of the 
BDNF-Val66Met-polymorphism on the pathophysiology of different 
neuropsychiatric disorders, including major depressive disorder, 
bipolar disorder, and schizophrenia (Autry and Monteggia, 2012). 
Post-mortem studies in schizophrenia patients have displayed 
evidence of reduced BDNF expression in the prefrontal cortex 
(Takahashi et al., 2000; Weickert et al., 2003; Hashimoto et al., 2005) 
and the hippocampus (Iritani et al., 2003; Durany and Thome, 2004). 
However, conflicting evidence has been reported on the impact of 
the BDNF-Valin-66-Methionine (Val66Met)-polymorphism on the 
age of onset, symptom severity, and MR-based brain volumes in 
schizophrenia (Pezawas et al., 2004; Numata et al., 2006; Naoe et al., 
2007; Pillai, 2008; Dutt et al., 2009; Gruber et al., 2012).
Given the involvement of BDNF in neurotransmission and 
memory processes, previous studies using non-invasive brain 
stimulation have examined the relationship between the 
BDNF-Val66Met-polymorphism and motor-cortical plasticity 
(Chaieb et al., 2014). Studies using intermittent and continuous 
theta-burst stimulation showed conflicting findings for either 
decreased or absent responses in healthy met-allele carriers 
(Cheeran et al., 2008; Antal et al., 2010; Jayasekeran et al., 2011) 
or no differences between val-homozygotes and met-allele car-
riers (Li Voti et al., 2011; Mastroeni et al., 2013). Related results 
have been reported for plasticity induction by paired-associa-
tive stimulation (PAS), showing either reduced effects of PAS in 
met-allele carriers (Cheeran et al., 2008) or no group differences 
(Witte et al., 2012). With regards to the after-effects of transcra-
nial direct current stimulation (tDCS), two studies using cathodal 
tDCS showed no differences between val-homozygotes and met 
carriers (Antal et al., 2010; Di Lazzaro et al., 2012) and a more pro-
nounced increase of cortical excitability in met carriers following 
anodal tDCS (Antal et al., 2010). No significant differences were 
observed following transcranial random noise stimulation (Antal 
et al., 2010). A decreased response of met carriers was found in 
a homeostatic plasticity paradigm, pairing cathodal tDCS with 
1Hz repetitve transcranial magnetic stimulation (repetitive TMS; 
Cheeran et al., 2008). The assessment of use-dependent plasticity 
showed reduced changes in motor cortical excitability in met car-
riers (Kleim et al., 2006). In one animal study, Fritsch et al. (2010) 
showed decreased BDNF secretion and long-term potentiation 
(LTP) following anodal tDCS in BDNF-mutant mouse primary 
motor cortex (M1) slices. Although the origin of these conflicting 
results has yet to be clarified, these studies suggest an associa-
tion of the BDNF-Val66Met-polymorphism with the susceptibil-
ity to induce plasticity using non-invasive brain stimulation.
In patients with schizophrenia, impairments of neuroplas-
tic responses following different forms of non-invasive brain 
stimulation have been consistently reported (Oxley et al., 2004; 
Hasan et al., 2011, 2013). Despite a likely impact of BDNF on the 
pathobiology of schizophrenia, the effects of the BDNF-Val66Met-
polymorphism on cortical plasticity and on cortical excitability 
following non-invasive brain stimulation in patients with schizo-
phrenia have not yet been investigated. Therefore, the aim of the 
present proof-of-concept study was to address this question for 
the first time by applying anodal and cathodal tDCS to the M1 
of schizophrenia patients and healthy controls and by monitor-
ing excitability changes before and after tDCS with single- and 
paired-pulse TMS paradigms. Paired-pulse TMS paradigms inves-
tigate the interaction of a first, sub-threshold conditioning stimu-
lus followed by a second, suprathreshold test stimulus (Kujirai 
et al. 1993). Short intervals between both stimuli (2–5 ms) result 
in a subsequent inhibition of the test pulse (short-interval corti-
cal inhibition [SICI]), whereas longer intervals (7–20 ms) lead to 
a facilitation (intracortical facilitation [ICF]; Kujirai et  al. 1993). 
Pharmacological challenges in healthy subjects strongly indicate 
that SICI is mediated via GABAA-neurotransmission, whereas ICF 
is related to glutamatergic neurontransmission (Ziemann, 2004). 
For tDCS, animal and human data indicate that the excitability 
changes following tDCS are long lasting, N-methyl-D-aspartate 
(NMDA)-dependent, and also polarity-dependent, and thus can 
be considered to be related to LTP (anodal) and long-term depres-
sion (LTD; cathodal). We first hypothesized that healthy and 
schizophrenia met-allele carriers would show reduced cortical 
inhibition and enhanced cortical facilitation compared to the 
respective val-homozygotes. Second, we hypothesized met-allele 
carriers would display less plasticity responses following tDCS 
compared to the val-homozygotes.
Methods
Subjects
In total, the data of 35 healthy controls and 22 schizophrenia 
patients from two foregoing studies (Hasan et  al., 2011; Hasan, 
Nitsche, et  al., 2012) were analyzed with regard to BDNF geno-
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experiments for anodal and cathodal tDCS, each study group was 
considered to be independent. All schizophrenia patients, but 
not all healthy controls, received both stimulation polarities (see 
Table 1). After giving written informed consent, genotyping was 
conducted on 22 participants with schizophrenia (SZ; 8 female, 
14 male, mean age = 30.1 years) and 35 healthy control (HC) par-
ticipants (14 female, 21 male; anodal group: mean age = 27.1 years; 
cathodal group: mean age = 27.8 years). The local ethics commit-
tee of the University Medical Centre Goettingen approved the pro-
tocol, which was conducted in accordance with the Declaration of 
Helsinki. Participants with contraindication to TMS or tDCS, such 
as neurological illness, severe brain injury, dermatological disor-
ders, brain tumors, or a history of dementia, and patients with 
concomitant benzodiazepine or mood stabilizer treatment were 
excluded. A clinical psychiatrist, blinded to the aims of the study, 
and a member of the study group (TW or AH) made an ICD-10 
consensus diagnosis. All participants underwent a standardized 
test of hand preference (Annett, 1970) and all patients received an 
assessment of psychopathological symptoms (PANSS; Kay et al., 
1987), disease severity (Guy and Bonato, 1976), and social function-
ing (Endicott et al., 1976). All schizophrenia patients (apart from 
three) were treated with antipsychotics (CPZ mean = 356.7 ± 393.5; 
12 patients received monotherapy: of these, 5 patients were treated 
with risperidone, 6 with quetiapine, and 1 with olanzapine). In 
general, patients did not receive a concomitant medication (e.g., 
antidepressants, antihypertensive drugs, or benzodiazepines).
TMS Procedure
The complete protocol has been described previously (Hasan 
et al., 2011). Briefly summarized, subjects were examined in a 
comfortable sitting position with arms supported passively. 
Electromyographic activity was recorded by surface electrodes 
placed over the right first-dorsal interosseus muscle (FDI). Raw 
signals were amplified, bandpass-filtered (2–10 kHz) and digi-
tized using a standard amplifier (Keypoint Portable, Medtronic 
Co.). TMS was performed over the left M1 with a standard 70 mm 
TMS figure-of-eight magnetic coil and a MagPro X 100 magnetic 
stimulator (Medtronic Co.). Throughout all experiments, the coil 
was held tangentially to the head, with the handle pointing 
backwards and in a 45° angle lateral to the midline. The stimu-
lation site that produced the largest motor-evoked potential 
(MEP) at moderately suprathreshold stimulation intensities was 
defined and marked as the optimal coil position.
tDCS Procedure
Transcranial direct current stimulation was applied after base-
line TMS examination. The tonic electrical field with a stimu-
lation intensity of 1 mA was induced using a CE-certified 
stimulator (DC-Stimulator-Plus, NeuroConn GmbH) through 
saline-soaked rectangular-surface sponge-electrodes (7 x 5 cm) 
for a duration time of 9 minutes in the cathodal and 13 minutes 
in the anodal condition (Nitsche et al. 2000, 2001). These stand-
ard stimulation durations have been consistently shown to be 
optimal for the induction of cortical excitability alterations last-
ing for about 1 h after tDCS (Nitsche et al., 2008). The stimulation 
electrode was placed over the left M1 on the spot of the optimal 
coil position, and the second electrode was placed over the con-
tralateral supraorbital forehead.
Cortical Excitability
Resting motor threshold (RMT), expressed as a percentage of 
maximum stimulator output, was defined as the lowest inten-
sity that produced a minimum MEP of 50 µV in the relaxed FDI 
in at least 5 of 10 trials. Single-pulse MEPs were recorded from 
the motor-cortical representation of the right FDI (MEP-size) to 
monitor the global effects of tDCS on cortico-spinal excitabil-
ity. TMS intensity was adjusted before tDCS to evoke MEPs of 
1 mV size on average (S1mV) and was kept unchanged for the 
after-effect assessment (Hasan et  al., 2011). Forty MEPs were 
recorded before tDCS and 5 min after the stimulation. Follow-up 
measurements of cortical excitability parameters were started 
immediately. The cortical silent period (CSP), a measure of corti-
cal inhibition, was obtained by recording from the FDI muscle 
under voluntary contraction while stimulating the contralateral 
M1 with 120% RMT. The mean CSP duration was calculated from 
10 trials. Short-latency intracortical inhibition and intracorti-
cal facilitation (SICI, ICF) were recorded with a standardized 
Table 1. Demographic and clinical characteristics of the participants. CGI: clinical global impression; CPZ: chlorpromazine equivalent dose; 
GAF: global assessment of functioning; PANSS: positive and negative syndrome scale. Data are presented as mean ± standard deviation. aChi2-
test; bone-way-ANOVA; #all schizophrenia patients participated in both anodal and cathodal tDCS within one week, resulting in the same psy-
chopathological scores, CPZ-equivalents, and duration of illness. HC either received only cathodal (n = 15) or only anodal (n = 13) tDCS or both 
stimulation paradigms (n = 7). All analyses were conducted for the anodal and cathodal samples as independent groups.
Variable SZ-val SZ-met HC-val HC-met Statistics
nges = 57
# n = 14 n = 8 n = 17 n=18
Gender 6 F, 8 M 2 F, 6 M 8 F, 9 M 6 F, 12 M p=0.693 a
Age (years) 36.79 ± 7.47 27.75 ± 7.34 30.29 ± 9.12 33.67 ± 9.73 p=0.080 b
Handedness 13 R, 1 L 8 R, 0 L 17 R, 0 L 16 R, 2 L p=0.436 a
BDNF
 val/val 14 - 17 -
 val/met - 8 - 18 p=0.438 a
PANSS Scores
 Total 58.50 ± 12.6 52.14 ± 10.4 - - p=0.264 b
 Positive 14.29 ± 5.2 11.71 ± 4.9 - - p=0.292 b
 Negative 16.21 ± 4.4 16.14 ± 3.6 - - p=0.971 b
 General 28.00 ± 5.8 24.29 ± 5.4 - - p=0.175 b
GAF 56.00 ± 11.0 64.43 ± 8.4 - - p=0.093 b
CGI 4.57 ± 0.65 3.86 ± 1.1 - - p=0.070 b
CPZ (daily) 382.55 ± 484.9 30.4.93 ± 122.3 - - p=0.685 b
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paired-pulse protocol (Kujirai et al., 1993; conditioning stimulus: 
80% RMT; test stimulus: intensity that produced resting MEPs 
averaging 0.7–1.3 mV [S1mV]; ISIs: 3 and 12). A minimum of 20 
trials with each ISI and 40 trials with the test stimulus alone 
were performed. RMT and S1mV were adjusted for the paired-
pulse protocols and for CSP after tDCS (Chen, 2004).
BDNF Genotyping
Genomic DNA was extracted from ethylenediaminetetraacetic 
acid anti-coagulated venous blood samples using the chemagic 
MSM I  system (PerkinElmer Chemagen Technologie GmbH). 
BDNF Val66Met (rs6265) was genotyped on a 7900HT Fast 
Real-Time PCR System (Life Technologies) using TaqMan®SNP 
Genotyping Assay C-11592758_10 (Life Technologies) and the 
standard protocol for allelic discrimination. Accuracy was 
assessed by duplicating 15% of the original sample, and repro-
ducibility was 100%.
Statistics
For statistical analysis, SPSS 22 for Windows (IBM) was used. 
Level of significance was set at α = 0.05 for gender, hand pref-
erence, and BDNF genotype. Chi2-tests were computed to test 
for different distributions between the study groups. One-way 
analysis of variance (ANOVA) was used to compare mean ages 
and baseline excitability between the groups. MEP size was 
calculated as the mean MEP amplitude both individually and 
then interindividually, both before and after stimulation. As 
the normality assumption was violated (Kolmogorov–Smirnov-
test, p between <0.001 and 0.007) for 1 mV-MEP, RMT, SICI, and 
ICF, square-root transformations were applied to meet the 
requirements for repeated-measures-ANOVA (RM-ANOVA). 
RM-ANOVAs were computed with time (baseline and post-
tDCS) as a within-subject factor and stimulation type (anodal, 
cathodal), BDNF genotype (val/val [val-group] and val/met and 
met/met [met-group]), and study group (SZ, HC) as between-
subject factors. Dependent variables were RMT, S1mV, MEP 
size, CSP, SICI, and ICF, at baseline and after tDCS stimulation 
(between-factor time [pre, post]). In cases of significant interac-
tion effects, independent-sample t-tests for inter-group com-
parisons and paired-sample t-tests for intra-group pre-to-post 
comparisons (all two-tailed; p < 0.05; not adjusted for multiple 
comparisons; adjusted values are presented in Supplementary 
Table  1) were conducted to detect different distributions 
between the groups. In cases of lacking interactions, no fur-
ther t-tests were conducted. In the linear models, sphericity 
was tested with the Mauchly’s test and, if necessary (Mauchly’s 
test <0.05), the Greenhouse-Geisser correction was used. Effect 
sizes for the between-group comparisons were calculated. 
Data in tables are presented as mean ± standard deviation; in 
all figures, error bars refer to the standard error and graphs 
show untransformed data.
Results
Sociodemographic and Clinical Characteristics
The study groups did not differ significantly with respect to 
gender distribution (p  =  0.693), handedness (p  =  0.436), or age 
(p  =  0.080). According to PANSS measures, patients suffered 
from moderate to severe positive and negative symptoms, likely 
accompanied by directed degrees of illness and impairments of 
social functioning (Table 1).
Distribution of Genetic Polymorphisms
No significant group differences were detected for the BDNF-
Val66Met-polymorphism (p = 0.438; schizophrenia patients (SZ)-
val: n = 14, 64,6%; SZ-met: n = 8, 36,4%; healthy-controls (HC)-val: 
n = 17, 48,6%; HC-met: n = 18, 51,4%; Table 1) and genotyping results 
did not deviate from the Hardy-Weinberg equilibrium (p = 0.11).
Cortical Excitability at Baseline
Overall ANOVA showed a significant difference between the 
val-homozygotes and met-allele carriers for ICF (F1,56  =  11.187, 
p = 0.002, η2 = 0.169). For all other baseline parameters, no dif-
ferences were observed. Further group comparisons of cortical 
excitability parameters at baseline were conducted between 
schizophrenia and healthy control val-homozygotes and met-
allele carriers (SZ-val, SZ-met, HC-val, and HC-met) by applying 
ANOVAs to both the anodal and the cathodal sample. Analysis 
of the anodal sample revealed a significant difference for ICF 
(F1,41 = 3.380, p = 0.028, η
2 = 0.211). Further independent-sample 
t-test analyses showed significantly higher baseline ICF in HC 
met-allele carriers compared to the HC val-group (t(18)  =  2.444, 
p  =  0.025, d  =  1.105). A  non-significant similar pattern was 
found when comparing the SZ met-group to the SZ val-group 
(t(20) = 1.746, p = 0.096, d = 0.766; Table 2 and Figure 1). For the 
cathodal sample, the ANOVA analysis revealed no significant 
group differences (F1,43 = 1.078, p = 0.369, η
2 = 0.075), though the 
data of the cathodal sample showed the same numeric dis-
tribution. It is possible,that, in contrast to our findings in the 
anodal sample, significant differences failed to be observed for 
the cathodal sample due to the higher standard deviations and 
due to a different BDNF-Val66Met-polymorphism distribution. 
No other variables showed differences across groups (Table 2).
In summary, we observed higher baseline ICF in healthy and 
schizophrenia met-allele carriers compared to the respective 
val-homozygotes. ICF represents the activity of facilitatory and 
glutamate-mediated cortical networks (Chen. 2004; Ziemann, 
2004) and the presented results indicate that the met-allele is 
associated with a cortical disinhibition.
Impact of tDCS on Cortical Excitability
RMT, S1mV, 1mV MEP. and aMEP
A RM-ANOVA for 1mV-MEP revealed significant effects of time 
× BDNF and time × stimulation, but no further interactions or 
main effects (all p ≥ 0.069; Table 3 and Figure 2). Since analyses 
did not show a significant time × BDNF × group × stimulation 
interaction, no further subgroup RM-ANOVAs were conducted.
However, to test whether tDCS induced a plasticity response 
at all, we performed paired-sample t-tests for MEP-amplitudes in 
all study groups. This showed an increase in MEP-amplitudes in 
all subgroups following anodal tDCS (SZ-val t(13) = 3.348, p = 0.005; 
SZ-met t(7) = 4.685, p = 0.002; HC-val t(11) = 4.020, p = 0.002; HC-met 
t(7)=3.374, p=0.012). In the cathodal condition, a plasticity 
response was observed in healthy subjects (HC-val t(9) = 2.682, 
p = 0.025; HC-met t(11) = 1.860, p = 0.090), but not in schizophrenia 
patients (SZ-val t(13) = 0.816, p = 0.429; SZ-met t(7) = 0.665, p = 0.527) 
in the cathodal group (Figure 2). One previous study with healthy 
subjects showed significant enhanced plasticity response (MEP 
amplitudes) following anodal tDCS and a trend towards a more 
pronounced decrease in excitability after cathodal tDCS in met-
allele carriers (Antal et al., 2010; Chaieb et al., 2014). To compare 
our results to this analysis, we conducted additional RM-ANOVAs 
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Table 2. Cortical excitability at baseline. aMEP: active MEP; CSP: cortical silent period; HC: healthy controls; ICF: intracortical facilitation; MEP: 
motor-evoked potential; RMT: resting motor threshold; S1mV: stimulation intensity to generate 1mV MEP; SICI: short-interval intracortical 
inhibition; SZ: schizophrenia patients;. -met: met-allele carriers; -val: val-homozygotes. Data are presented as mean ± standard deviation and 
bold letters plus asteriks (*) signifying p-values ≤0.05.
Variable n SZ-val n SZ-met N HC-val n HC-met ANOVA
Anodal sample
RMT (%) 14 53.7 ± 8.5 8 53.8 ± 5.6 12 48.8 ± 8.0 8 51.4 ± 3.7 F = 1.466 p = 0.239
S1mV (%) 14 61.5 ± 10.5 64.9 ± 9.9 58.5 ± 10.9 63.8 ± 8.2 F = 0.996 p = 0.405
1mV MEP (mV) 14 938.3 ± 219.3 953.3 ± 172.6 1049.3 ± 195.8 941.3 ± 210.1 F = 0.651 p = 0.587
aMEP (mV) 14 8458.9 ± 3268.2 10943.6 ± 3928.5 7709.9 ± 2244.0 9735.8 ± 3252.6 F = 1.017 p = 0.396
CSP (ms) 14 137.3 ± 40.9 165.5 ± 37.5 122.3 ± 42.8 132.3 ± 44.7 F = 1.819 p = 0.160
SICI 3ms (%) 14 31.9 ± 20.8 36.3 ± 18.1 27.1 ± 29.1 17.2 ± 11.9 F = 1.835 p = 0.157
ICF 12ms (%) 14 170.2 ± 86.5 240.9 ± 136.3 132.9 ± 49.0 202.8 ± 74.2 F = 3.380 p = 0.028*
Cathodal sample
RMT (%) 14 60.6 ± 8.0 8 58.6 ± 9.4 10 55.3 ± 7.1 12 56.2 ± 8.3 F = 0.930 p = 0.435
S1mV (%) 14 70.1 ± 10.4 66.8 ± 11.2 61.9 ± 9.6 62.3 ± 9.8 F = 1.588 p = 0.207
1mV MEP (mV) 14 969.9 ± 250.3 820.9 ± 233.9 958.9 ± 438.5 1020.3 ± 227.0 F = 1.033 p = 0.388
aMEP (mV) 14 6772.6 ± 3600.9 5792.3 ± 1384.2 6731.9 ± 2783.1 7629.9 ± 3050.5 F = 0.457 p = 0.714
CSP (ms) 14 146.7 ± 33.0 143.1 ± 41.2 115.5 ± 31.8 129.4 ± 39.0 F = 1.480 p = 0.235
SICI 3ms (%) 14 34.6 ± 32.2 35.6 ± 40.6 26.4 ± 28.1 48.1 ± 56.9 F = 1.078 p = 0.370
ICF 12ms (%) 14 177.3 ± 164.8 239.5 ± 200.0 134.2 ± 57.6 211.2 ± 106.4 F = 1.369 p = 0.267
increase in both HC val-homozygotes and HC met-allele carriers 
following anodal tDCS, demonstrated by a significant main effect 
for time (F1,18 = 27.827, p < 0.0001). However, the analysis of the 
time × BDNF interaction remained non-significant (F1,18 = 3.416, 
p = 0.081). Subsequent independent-sample t-tests of the post- 
tp pre-ratios showed a numeric difference for an augmented 
increase in excitability in the case of met-allele carriers com-
pared to val-homozygotes (t(18) = 1.912, p = 0.072, d = 0.799), con-
firming one foregoing study (Antal et al., 2010).
For cathodal tDCS, we found an MEP decrease in both 
healthy met carriers and val-homozygotes, as shown by a sig-
nificant effect of time (F1,20  =  11.491, p  =  0.003), but no further 
time × BDNF interaction (F1,20  =  2.135, p  =  0.159). Subsequent 
independent-sample t-tests of the post- to pre-ratios revealed 
no significant differences between met-allele carriers and val-
homozygotes (t(20) = 1.355, p = 0.191, d = 0.565), also confirming 
the findings of Antal et al. (2010). Neither analysis for the SZ sub-
jects showed a significant interaction or subgroup difference. 
RM-ANOVAs revealed no significant or trend-level effects for all 
other dependent variables (RMT, S1mV, and aMEP).
In summary, we were able to confirm previous findings (Antal 
et al., 2010; Chaieb et al., 2014) of an enhanced facilitatory plas-
ticity response in terms of increased MEP amplitudes following 
anodal tDCS and of no differences following cathodal tDCS in 
healthy met-allele carriers compared to val-homozygotes.
SICI, ICF, and CSP  
For SICI, the RM-ANOVA revealed significant effects of time × 
BDNF × group, time × group × stimulation, and time × BDNF × 
group × stimulation, but no further interactions or main effects. 
Subsequent RM-ANOVAs of the anodal and cathodal samples 
showed significant effects of time × BDNF × group in the cathodal 
condition, but not in the anodal condition (Table 3). Hence, no 
further analyses were conducted regarding the anodal-tDCS 
subgroup.
For cathodal tDCS, two separate subsequent RM-ANOVAs 
were conducted, and revealed a significant time × group effect 
for the met-allele carriers and no effect for the val-homozygotes.
To further investigate the impact of BDNF-Val66Met-
polymorphism in the cathodal subgroup, paired-sample t-tests 
were computed, and showed significantly lower SICI following 
cathodal tDCS in the SZ met-allele carriers (t(7) = 2.662, p = 0.0324), 
but not in the SZ val-homozygotes (t(13)  =  0.448, p  =  0.6617; 
Figure 3). The HC met-allele carriers showed a converse effect 
with significantly-pronounced SICI (t(11)  =  2.246, p  =  0.0462), 
and the HC val-homozygotes showed reduced SICI (t(9) = 2.400, 
p = 0.0399) following cathodal tDCS (Figure 3).
Independent-sample t-tests not corrected for multiple com-
parisons showed significantly lower SICI after cathodal tDCS 
for SZ patients compared to HC participants in the case of met-
allele carriers (t(18) = 2.5999, p = 0,0181, d = 1.123), but not for val-
homozygotes (t(22) = 0.3538, p = 0.7268, d = 0.144; Figure 3).
Neither baseline nor post-tDCS SICI values differed sig-
nificantly between val-homozygotes and met-allele carriers in 
either SZ (baseline: t(20) = 0.056, p = 0.956, d = 0.025; post-tDCS: 
t(20)  =  1.390, p  =  0.180, d  =  0.583) or HC (baseline: t(20)  =  1.191, 
p = 0.247, d = 0.513; post-tDCS: t(20) = 1.018, p = 0.321, d = 0.428). 
No significant effects were found by RM-ANOVAs run on CSP 
duration and ICF data.
In summary, we observed reduced SICI following cathodal 
tDCS in the schizophrenia met-allele carriers compared to the 
schizophrenia val-homozygotes. The healthy control met-allele 
carriers displayed a converse effect, showing significantly-
pronounced SICI after cathodal tDCS compared to the healthy 
val-homozygotes. As SICI involves GABA-mediated intracorti-
cal inhibitory networks, this result indicates that the met-allele 
influences inhibitory networks following cathodal tDCS in 
dependence of the diagnosis.
Correction for Multiple Testing
The presented uncorrected results of this proof-of-concept 
study do not provide broad evidence that can be generalized, 
and thus need to be considered as preliminary and confirmed 
in subsequent larger studies. However, to test the generalizabil-
ity of findings, Bonferroni-adjustment for multiple comparisons 
was performed for independent-sample t-tests (n = 6). Adjusting 
the results for these six subgroup comparisons results in the 
situation that the significant group differences presented in the 
paragraphs before did not survive correction for multiple test-
ing. Please see Supplementary Table 1 for a detailed presenta-
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Discussion
The results of this proof-of-concept study provide the first pre-
liminary evidence for BDNF-associated alterations in inhibitory 
cortical plasticity following tDCS in schizophrenia patients and 
for an impact of the BDNF met-allele on cortical facilitatory 
networks. More specifically, schizophrenia met-allele carriers 
showed reduced SICI following LTD-inducing cathodal tDCS, 
whereas healthy met-allele carriers displayed the opposite 
effects. These effects could be observed neither in val-homozy-
gotes nor following LTP-inducing anodal tDCS. The baseline 
increase in ICF can be considered to be hyperexcitable, and 
indicates impaired inhibitory regulatory processes in met-allele 
carriers independent from disease state. Our preliminary find-
ings enable a novel view of the inhibitory and plasticity deficits 
in schizophrenia patients and extend prior findings of BDNF-
induced alterations of cortical plasticity in healthy subjects.
BDNF Effects on Cortical Excitability
Met-allele carriers had more ICF before tDCS compared to the 
val-homozygotes, indicating motor-cortical hyperexcitability. It 
has been suggested that ICF is generated in excitatory neural 
circuits of the motor cortex, which are at least partially distinct 
from the SICI-generating circuits (Chen, 2004; Ziemann, 2004). 
For ICF generation, the excitation balance is shifted from inhibi-
tion towards facilitation, whereas the inhibitory processes are 
controlled by GABA-mediated inhibitory postsynaptic potentials 
(Connors et al., 1988; Ziemann, 2004). Pharmacological challenges 
in healthy subjects further indicate that ICF critically depends on 
the activity of NMDA and GABAergic receptors, as both NMDA-
receptor antagonists and GABA agonists decrease ICF (Ziemann 
et al., 1996, 1998; Schwenkreis et al., 1999). Therefore, one could 
speculate that the met-allele, largely independent from disease 
state, leads to motor-cortical hyperexcitability as the result of an 
increased facilitation mediated by NMDA and GABA receptors. 
However, SICI, a marker of GABAergic intracortical inhibition 
(Ziemann, 2004), did not differ significantly at baseline between 
val-homozygotes and met carriers in both groups. This could 
indicate the observed increase in ICF in the met-allele carriers 
is mainly mediated by a glutamatergic pathway with less influ-
ence of GABAergic neurotransmission.
BDNF Effects on Neuroplasticity
Following LTD-inducing cathodal tDCS, SICI was reduced in 
schizophrenia met-allele carriers, but pronounced in healthy 
met-allele carriers. Healthy controls showed a numeric MEP 
increase in met-allele carriers following anodal tDCS. Genotype 
had no influence on the decrease of MEPs following cathodal 
tDCS. In schizophrenia patients, genotype did not influence the 
tDCS-mediated MEP modulation in both stimulation polarities.
Previous research addressing the influence of the BDNF-
Val66Met-polymorphism on different measures of neural 
Figure 1. Intracortical facilitation at baseline. (A) ICF (anodal sample) shows sig-
nificant differences regarding baseline ICF across all groups and between HC-val 
compared to HC-met, as well as a trend-level difference between SZ-val and 
SZ-met. (B) ICF (cathodal sample) shows no significant differences regarding 
baseline ICF across all groups (*p ≤ 0.05). Data are presented as mean ± standard 
error of the mean.
Table 3. Results of RM-ANOVAs for SICI values. RM-ANOVAs show 
significant time × BDNF × group, time × group × stimulation, and 
time × BDNF × group × stimulation interactions for SICI values in the 
whole sample and significant time × BDNF × group and time × group 
interactions for SICI values in the cathodal subsample and bold let-
ters plus asteriks (*) signifying p-values ≤0.05.
Hypothesis  
df, error df F value p value
1mV-MEP values (whole sample)
Time 1, 78 11.128 0.001*
Time x BDNF 4.267 0.042*
Time x Group 1.360 0.247
Time x Stimulation 38.399 <0.001*
Time x BDNF x Group 0.978 0.326
Time x BDNF x Stimulation 0.162 0.688
Time x Group x Stimulation 3.404 0.069
Time x BDNF x Group  
x Stimulation
0.858 0.357
SICI values (whole sample)
Time 1, 78 0.361 0.550
Time x BDNF 2.342 0.130
Time x Group 0.574 0.451
Time x Stimulation 2.497 0.118
Time x BDNF x Group 0.284 0.596
Time x BDNF x Stimulation 4.125 0.046*
Time x Group x Stimulation 4.595 0.035*
SICI values (cathodal sample)
Time 1, 40 0.875 0.355
Time x BDNF 0.471 0.496
Time x Group 6.568 0.014*
Time x BDNF x Group 12.672 0.001*
SICI values (anodal sample)
Time 1, 38 0.013 0.909
Time x BDNF 2.279 0.139
Time x Group 0.170 0.682
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plasticity has shown heterogeneous and partly contradictory 
results that point to a possible reduction in hippocampal vol-
ume (Egan et  al., 2003; Pezawas et  al., 2004; Molendijk et  al., 
2012), reduced hippocampal activation (Hariri et al., 2003), and 
lower performance in episodic memory tasks (Hariri et al., 2003; 
Dempster et  al., 2005; Goldberg et  al., 2008; Kambeitz et  al., 
2012) in healthy met-allele carriers. Evidence from non-invasive 
brain stimulation studies indicates an association of the BDNF-
Val66Met-polymorphism with altered neuroplasticity in healthy 
controls. Three previous studies have used tDCS to examine this 
relationship (Cheeran et al., 2008; Antal et al., 2010; Di Lazzaro 
et al., 2012). Di Lazarro et al. (2012) reported no significant dif-
ferences between val-homozygotes and met-allele carriers with 
respect to MEP size, SICI, or ICF following cathodal tDCS. In con-
trast, Antal et al. (2010) found more pronounced after-effects of 
both anodal and cathodal tDCS in addition to no response to 
iTBS in the case of met-allele carriers. No significant differences 
were observed following tRNS. The third study, by Cheeran et al. 
(2008), showed reduced or absent after-effects following iTBS and 
cTBS in met carriers, a decreased response to PAS, and decreased 
reversal of cathodal tDCS-induced inhibition through 1Hz-rTMS 
(homeostatic plasticity). Our results in healthy subjects princi-
pally confirm the findings of Antal et al., showing a trend towards 
a more pronounced enhancement of MEPs after anodal tDCS, 
and also extend this previous study by showing increased SICI 
following cathodal tDCS in healthy met-allele carriers. Taken 
together, these findings are indicative of a complex interaction 
between the BDNF-Val66Met-polymorphism, LTD-like plastic-
ity, and intracortical facilitatory networks in healthy subjects. 
Regarding the inconsistencies between the findings reported by 
Di Lazarro et al. and Antal et al., as well as our study, differences 
between the duration of the applied tDCS paradigms should be 
taken into account. In experimental setups by both Antal et al. 
and our group, tDCS was performed for 9 minutes (cathodal) and 
13 minutes (anodal), whereas cathodal tDCS was conducted for 
20 minutes in Di Lazzaro et al.’s study (2012). Furthermore, one 
should note that none of the foregoing studies (Cheeran et al., 
2008; Antal et al., 2010; Di Lazzaro et al., 2012) reported the allele 
frequency, meaning that we cannot rule out varying allele fre-
quency in accounting for differences across studies.
In healthy met-allele carriers, the observed higher intracorti-
cal facilitation at baseline and the increased intracortical inhi-
bition following cathodal tDCS might be explained by higher 
baseline glutamatergic activity, resulting in increased efficacy 
of cathodal tDCS due to a larger range for plasticity modula-
tion. Following the assumption of a potentially larger gain 
between baseline hyperexcitability and cathodal tDCS, we did 
not observe the same after-effects in schizophrenia met-allele 
carriers. The reduced SICI following cathodal tDCS could possi-
bly be interpreted as being due to impaired plasticity regulation 
as a consequence of disturbed homeostatic regulation. Another 
possible explanation is that the observed effect in schizophrenia 
met-allele carriers is related to reduced GABAergic interneuron 
activity. Previous studies have consistently reported a reduction 
of SICI in subjects at risk of developing psychosis, in first-epi-
sode patients, and in chronically ill patients, and have assumed 
a relationship with reduced GABAergic interneuron inhibition 
(Wobrock et al., 2010; Hasan, Wobrock, et al., 2012; Bunse et al., 
2014; Rogasch et al., 2014). However, the lack of significant dif-
ferences in baseline SICI would favor a predominant gluta-
matergic effect. Remarkably, healthy met-allele carriers also 
displayed ICF baseline alterations without impairments in SICI 
regulation following cathodal tDCS, while neither schizophre-
nia nor healthy val-homozygotes displayed these deficits. Thus, 
Figure 2. MEP size before and after anodal and cathodal tDCS. Panels A and B display MEP sizes before and after anodal tDCS in healthy and schizophrenia val-homozy-
gotes and met-allele carriers. Panels C and D display MEP sizes before and after cathodal tDCS in healthy and schizophrenia val-homozygotes and met-allele carriers. 
Following anodal tDCS, increased MEP amplitudes were observed in all subgroups (SZ-val t(13) = 3.348, p = 0.005; SZ-met t(7) = 4.685, p = 0.002; HC-val t(11) = 0.002; HC-met 
t(7) = 0.012). Following cathodal tDCS, decreased MEP-amplitudes were observed in healthy subjects [HC-val t(9) = 2.682, p = 0.025; HC-met t(11) = 1.860, p = 0.090], but not 
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one could speculate that the BDNF-met allele in schizophrenia 
patients reduces the regulation of cortical excitability by means 
of reduced homeostatic regulation.
Neuropathological findings provide evidence for alterations 
in the GABA synthesis pathway, showing reductions of glutamic 
acid decarboxylase (GAD67) expression and density of GABAergic 
interneurons in various cortical areas, including the prefrontal 
and the motor cortex, of schizophrenia patients (Benes et  al., 
1991; Lewis et  al., 2005; Hashimoto et  al., 2008; Benes, 2011). 
Further neuropathological investigations showed BDNF-related 
GABAergic deficits in the prefrontal cortices of schizophrenia 
patients that are regulated by micro-RNA195, indicating deficits 
in the gene expression of inhibitory interneurons as a result of a 
complex interplay of coding and noncoding transcripts (Mellios 
et  al., 2009). Beyond that, post-mortem findings displayed 
reduced BDNF concentrations in cortical and subcortical areas, 
leading to disturbed neural plasticity mediated by reduced neu-
ronal trophic support (Takahashi et al., 2000; Durany et al., 2001; 
Weickert et al., 2003). In another study, BDNF expression levels 
and the mRNA of its receptor tyrosine kinase TrkB were found 
to be decreased in the prefrontal cortex of two schizophrenia 
cohorts (Hashimoto et al., 2005). Based on the observation that 
BDNF-TrkB signaling has an influence on the development of 
GAD67 and parvalbumin-positive GABAergic neurons (Huang 
et al., 1999; Cotrufo et al., 2003), the authors hypothesized that 
the impairments of BDNF-TrkB signaling in schizophrenia might 
be an upstream event contributing to the altered expression of 
GABA-related genes in schizophrenia (Takahashi et  al., 2000). 
Another neuropathological investigation failed to reveal the 
expected difference in GAD67 mRNA expression of schizophre-
nia patients hetero- or homozygous for the met-allele, but did 
show the expected reduction when compared to val-homozy-
gotes (Hashimoto and Lewis, 2006). Although the molecular and 
cellular processes of the observed alterations in ICF at baseline 
and in SICI following cathodal tDCS in schizophrenia met-allele 
carriers remain elusive, our results provide the first evidence for 
BDNF-related alterations with respect to the balance between 
excitation and inhibition.
Limitations
The major limitation of this study is that subjects were not 
genotyped before the physiological experiments. Therefore, no 
matching for number, age, gender, medication, or genotype dis-
tribution was conducted. However, no significant group differ-
ences were observed with respect to the biometrical data, and 
chlorpromazine equivalents and the allele frequency met the 
expectations of the Hardy-Weinberg equilibrium. In general, 
one should note the impact of any neuroactive medication on 
tDCS after-effects in patient studies. As a further limitation, the 
experiments were conducted by two different persons. However, 
the same stimulation protocol was conducted on all participants 
using the same stimulator, the same coil types, and the same 
settings in all experiments. For this reason, all four study groups 
were considered to be independent, whereas all schizophrenia 
patients, but only some healthy controls, participated in both 
experimental sessions. Another limitation is that it is not only 
BDNF that contributes to the pathophysiology of schizophrenia, 
but rather an interaction of various genes. Analyses of these 
gene interactions are beyond the scope and technical possibili-
ties of the experiments presented here. Though being within 
the sample size of other related physiological studies conducted 
on healthy subjects (Cheeran et  al., 2008; Nitsche et  al., 2008; 
Antal et al., 2010; Jayasekeran et al., 2011; Di Lazzaro et al., 2012; 
Chaieb et al., 2014), our sample size is rather small, maybe lead-
ing only to some numeric differences between groups that did 
not reach significance. Therefore, our results should be consid-
ered as preliminary and need to be replicated in larger samples 
of schizophrenia patients and healthy controls.
Summary and Outlook
In summary, this proof-of-concept study shows for the first 
time an impact of BDNF-Val66Met-polymorphism on LTD-
like plasticity following cathodal tDCS and on motor-cortical 
inhibitory and facilitatory networks in healthy controls and 
schizophrenia patients. Our findings may indicate that, in 
schizophrenia patients, the met-allele results in impairments 
of GABAergic and glutamatergic neurotransmission following 
plasticity induction. These results not only have the poten-
tial to provide a new view on the interaction of BDNF and the 
regulation of the inhibition-facilitation balance in humans, 
but might have considerable implications for clinical practice. 
Different techniques of non-invasive brain stimulation, like 
rTMS or tDCS, have been suggested to offer new possibilities 
in schizophrenia treatment (Hasan et al., 2013). However, the 
stimulation after-effects (Ridding and Ziemann, 2010) and 
the clinical efficacy (Freitas et  al., 2009) are subject to large 
Figure 3. Short-interval intracortical inhibition before and after cathodal tDCS. 
Panel A shows significant differences between baseline and post tDCS SICI val-
ues within the met-SZ and met-HC groups, as well as between met-SZ and met-
HC after tDCS. Panel B shows significant differences between baseline and post 
tDCS SICI values within the val-HC group, but not in the val-SZ group (*p ≤ 0.05). 
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inter-subject variability. According to the preliminary results 
of our study, BDNF-Val66Met-polymorphism might contribute 
to this variability, but future studies with larger sample sizes 
need to address this hypothesis specifically by linking BDNF 
genotype to clinical efficacy following non-invasive brain 
stimulation.
Supplementary Material
For supplementary material accompanying this paper, visit 
http://www.ijnp.oxfordjournals.org/
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